White paper image
TrialCard offers a number of resources that address current trends in the pharmaceutical industry.

Our Capabilities Brochures provide details on all of our service offerings, while our Public Relations Media Brochure features a collection of insights from key opinion leaders in the patient access and broader pharmaceutical space, and our White Papers offer specific examples of how we have helped our manufacturer clients increase patient engagement and achieve more positive outcomes.

Check the box next to the items you would like to receive, then scroll to the bottom of the page and click Submit.

Capabilities Brochures

Capabilties Brochure Image
Capabilities Brochure Our capabilities brochure provides detail on each of our service offerings, from our full suite of patient access and support (HUB) services which includes benefits investigation and verification, prior authorization and appeals support, specialty pharmacy triage, adherence messaging, nursing outreach and support, as well as co-pay and voucher patient affordability programs, tele-detail and tele-promotion campaigns, patient lead generation programs, and data reporting and analytic consulting services.

Public Relations Media Brochures

Public Relations Brochure Image
Public Relations Media Brochure Our Public Relations Media Brochure features a collection of resources from key industry thought leaders around topics that are critical in today’s healthcare landscape. Learn from experts in the patient access and affordability space and discover insights that help drive greater value from patient support programs.

White Papers

Please make your selections below:

White Paper Image
Using Co-Pay Programs to Acquire and Engage Patients
While co-pay offset programs make medicines affordable for patients, they have benefits that go way beyond simply reducing prices. Using these programs to acquire and engage patients can lead to better adherence, but also to new connections with both physicians and pharmacies and multiple benefits to pharmaceutical manufacturers.

Driving Greater Access to Healthcare Professionals and Increasing Brand Performance – How Virtual Engagement Is Becoming a Must-Have Component of Any Pharmaceutical Sales Strategy
Virtual engagement strategies are evolving the way the pharmaceutical industry connects with key stakeholders. By using a blend of technology and experienced personnel to seamlessly connect brands to healthcare professionals, virtual engagement offers a solution to the trend of decreased in-person engagement opportunities via the traditional field representative model.

Outbound Virtual Engagement: The Brand Manager’s Tool for Covering Whitespace and Vacant Sales Territories
Pharmaceutical brand marketers consistently face two challenges in structuring their sales forces – penetrating hard to reach whitespace territories, and maintaining prescriptions in vacant territories during the time they are uncovered. Successfully addressing these two concerns can be the difference between driving increased brand performance and simply maintaining the status quo or worse, losing market share to competitors.

I Need to Transition My HUB Program. What Do I Do Next?
This white paper examines the complex challenge of transitioning a patient support program in an abbreviated time frame. In one example cited, TrialCard transitioned over 93,000 patients and onboarded 36 case managers in a shortened time period as compared to average program-transition time in the industry.

Optimized ROI- The Need for Deeper Evaluation Measures to Maximize Co-pay Savings Program Results
ROI is commonly regarded as the gold standard of business evaluation. Analysts, marketers, and investors alike all speak of those magical three letters as the consummate indicator of a project’s success. High ROI means money well spent, while a suboptimal ROI is a black mark and almost certain precursor to an effort’s termination. But in the co-pay savings program space, ROI only tells a small part of the story when judging a program’s overall effectiveness. A deeper dive into the data strongly suggests that there are additional evaluation measures that can help paint the full picture of a program’s value to the brand marketer.

“Supercharging” Co-Pay Program Performance through Outbound Virtual Engagement: A Brand Marketer’s Weapon against Program Plateaus
Co-pay savings programs are often seen by pharmaceutical marketers as having an upper limit on how effective they can be in increasing brand performance. While they can certainly drive new patient starts and promote continued adherence, they aren’t without their challenges. One of the most prominent is that they are not infinitely scalable and their effectiveness will eventually reach a “leveling off” point. Brands desiring an upward surge in activity brought about by a co-pay offer are often left without an option – or are they? This white paper examines how adding an outbound virtual engagement solution enabled a top allergy brand to break through a program plateau to continue driving new patient starts.

No Patient Left Behind... Connecting Rare Disease Patients to Orphan Drug Manufacturers
If you have ever worked with Orphan Drugs, you know finding appropriate patients is a major commercial challenge. Pharmaceutical sponsors of Orphan Drugs often lack the infrastructure and capabilities necessary to identify physicians who diagnose, treat, and manage these rare patients. TrialCard developed a proven model for making this critical match and has helped many patients gain access to the therapy they so desperately need. In a recent 2015–2016 program, TrialCard’s “Detective Model” approach to locating patients with a specific rare disease returned tenfold more leads back to the pharmaceutical sponsor than forecasted.

Co-Pay Card Program Optimization Saves Manufacturer $13M
Program optimization analyses use transactional claim data to help brand marketers identify areas where their co-pay program is underperforming. Based on these findings, the program is then course-corrected to garner greater impact. This paper examines the specific case of one manufacturer that, through optimization analysis, realized nearly $13 million in cost savings from corrections made to their programs.

Are Co-pay Savings Programs the Best Acquisition Vehicles We Have?
Pharmaceutical brand marketers have traditionally viewed co-pay savings programs in a vacuum, as simply a mechanism that helps attract and retain patients and ultimately increase prescriptions filled. While this use of co-pay programs clearly generates positive results, these programs can be used for purposes that go well beyond that of providing affordable access to medications. By leveraging co-pay support programs as front-end patient acquisition tactics, marketers can use them as a means of engaging patients in the brand’s integrated and multifaceted marketing stream, thereby increasing opportunities for both brand success and improved patient outcomes.

TC Market Access Launched to Deliver Patient-Centric HUB Services Driven by Technology and Pulse Analytics
Continued growth in the HUB space and a demonstrated need in the marketplace for integrated, patient-centric soultons, TrialCard has established TC Market Access as its dedicated HUB division.

Why Integrated HUB Solutions Are Proving a Necessity for Buy and Bill Specialty Products
This white paper examines the success of specialty medications that have coupled their buy and bill cost-sharing assistance program with a fully integrated HUB solution to support the patient with their affordability needs as well as with infusion/injection administration, appointment scheduling support, and care coordination.

Leveraging Data and Analytics to Enhance CoPay Program Performance
By utilizing data to understand specific reasons for non-adherence and the ideal timing, content, and channel for intervention, manufacturers can create more successful patient engagement strategies that help influence a shift toward better compliance with therapy.

Leveraging Patient Feedback Data to Support Effectiveness and Demonstrate Outcomes
As the healthcare landscape moves increasingly toward outcome-based treatment approaches, the need to gather and analyze real-world outcome data has become paramount to gauging medication effectiveness and subsequently recruiting prescribers as brand advocates. This study outlines a feedback program that provides prescribers with patient results of their treatment experience in order to better inform their therapy recommendations. The program is designed to offer a unique value proposition to both patients and physicians to drive increased participation in their treatment.

Adherence: Leveraging Data to Enhance Your Brand’s Ability to Reach Target Patients
By utilizing data to understand specific reasons for non-adherence and the ideal timing, content, and channel for intervention, manufacturers can create more successful patient engagement strategies that help influence a shift toward better compliance with therapy.

A Winning Approach to Program Transition: Unique Program Design and Multichannel Communication Strategy Delivers Unparalleled Results
TrialCard has a proven track record of successfully transitioning existing patient access and affordability programs while improving the patient experience and growing brands. This case study examines the unique co-pay program design and transition strategy TrialCard developed and executed for a top allergy brand. These improvements helped maximize program impact, resulting in total incremental revenue exceeding 24M.

Pharmaceutical Executive White Paper - Hiding in Plain Sight
Co-Pay Support Programs provide the entrée to better outcomes precisely because it’s one of the best vehicles for engaging patients. Because patients regularly come back to Co-Pay Support Programs when it’s time for a refill, they offers tremendous leverage and opportunity to engage with patients on more matters than simple Co-Pay and financial assistance: be that for behavioral profiling, adherence support, education, or real-world evidence.

Leveraging Data & Analytics to Enhance Co-pay Program Performance
Good analytics can catapult a program to greater levels of success. In this White Paper, discover the specific data points that identify and reduce the number of "walkaways" (i.e. patients who decide not to purchase a prescription).

Increasing ROI Through Adherence
Healthcare providers agree that the toughest challenge to treating patients is neither the effectiveness of their medication, nor issues with access and affordability. It's getting the patient to take their medicine as prescribed. And for the brand marketer, the new growth frontier resides on the sloping shoulders of patient adherence. This draws on new research to investigate how different branded promotional tactics affect adherence rates.

How TrialCard Helped a Specialty Pharmacy Product Company Increase Patient Access
Small brands shouldn’t have to settle for standardized “out of the box” patient access solutions. Small brands should demand that their unique, unmet challenges be solved by employing “team think” innovation and tireless customer service.

RxSaver ROI Results
Prescription Abandonment can be solved. When a prescription is abandoned, nobody wins. The pharmaceutical brand loses a prescription. The pharmacist loses a customer. The patient loses the clinical benefit of a prescription medication that was prescribed for him/her. To win, pharmaceutical brands, pharmacists, and patients need an abandonment solution. RxSaver is the first solution for prescription abandonment.

The Role of Analytics in Co-Pay Assistance Programs
Key measures that TrialCard has invested in to ensure that we can provide our clients the assurance that their promotions are generating positive returns

Hiding in Plain Sight : Could Co-Pay Programs Be the Solution for Better Outcomes?
Everyone knows the old saw that Willie Sutton said that he robbed banks because that was where the money was. There was a certain logic that the famed bankrobber had that is pretty relevant to the ways of Co-Pay, too – though before anyone panics about the parallel, let me explain! The healthcare industry has been wringing its collective hands for years about the problems surrounding “patient engagement.” Beyond the fact that no one has a really good definition of what constitutes patient engagement, most everyone agrees that if you have more patient engagement, you’ll achieve better outcomes.

Moments of Truth : How Pharmacies Are Becoming a Brand's Best Opportunity
With traditional pharmaceutical brands marketing channels narrowing, pharmacists are growing in their role as key health care providers for brand managers to reach.

How TrialCard’s Patient Feedback System Helped a Brand Achieve a 60% Increase in NRx
TrialCard’s vision and strategic philosophy is to support branded pharmaceutical manufacturers in marketing medicines through the strategy, design, and execution of innovation solutions. The case study that follows demonstrates TrialCard’s ability to support a brand’s unique challenges with a customized solution.

Integrated Life Cycle Patient Access Solutions that Maximize Brand ROI
Pharmaceutical brand marketers are facing a paradigm shift in the way they market patient access solutions. As they navigate through the dynamics of a regionalized market, shrinking budgets and the challenges of tactical implementation they require a consultative relationship with vendor providers. Can the pharmaceutical marketer really rely on 1 vendor to deliver customized, innovative solutions over the life of their brand?

How the Affordable Care Act Made Co-Pay Programs a Requirement for Patient Access
How the multi-tiered formularies of ACA QHP’s place the burden of cost on the patient and limit a brand’s access to patients.

How do the Affordable Care Act and Anti-Kickback Statute impact a patient’s eligibility for co-pay programs?
TrialCard’s Affordable Care Act Task Force reviews the legal, regulatory, and business impact of the Affordable Care Act on the pharmaceutical industry.


Newsletters Image
TrialCard Patient Access Prescription Vol 1 October 2015
The healthcare industry has been wringing its collective hands for years about the problems surrounding “patient engagement.” Beyond the fact that no one has a really good definition of what constitutes patient engagement, most everyone agrees that if you have more patient engagement, you’ll achieve better outcomes.

TrialCard Patient Access Prescription Volume 2 April 2016
-Key Considerations for Selecting a HUB Services Provider for My Specialty Brand -Tele-promotion as a Solution to Locating Orphan Drug Patients -Nurses Are the Key to Delivering Improved Patient Outcomes


Capabilties Brochure Image
Pharma Enters the EHR Era
Featured by Medical Marketing and Media, this eBook offers trends, insights and advice for pharma on this fast-shifting and imperfect area of healthcare technology.

New Days, New Ways for Co-pay
Featured by Medical Marketing and Media; offers analysis, trends, and expert advice for biopharma on optimizing use of co-pay cards, adherence, and other patient support interventions

Innovations In Oncology
Featured by Medical Marketing and Media. Provides a medical and commercial trend report for marketers of anti-cancer modalities.

Patient Access
This eBook, featured by Medical Marketing and Media, describes the latest insights, innovations, and intel on the state of patient access.


Webcast-Icon Image
Improving Co-Pay Program Performance Using Patient Engagement
Even the most successful pharmaceutical brand managers preside over co-pay programs that struggle to successfully recapture patients who have activated, but never used a co-pay card. These same managers also strive to re-engage with patients who are late to refill a prescription. In this webcast, Paul LeVine examines how TrialCard can help to alleviate these concerns while recapturing lost revenue due to both of these common problems.

What Does Success Look Like in Patient Affordability?
In this Medical Marketing and Media webcast TrialCard's Vice President of Analytics Paul LeVine speaks about key success markers for patient affordability programs, and how brands can more accurately gauge program performance and value.

Patient Speed to Therapy: The Anchor to a Successful Hub Solution
In this Medical Marketing and Media webcast TrialCard's Vice President of Market Access Solutions Scott Dulitz examines how top HUB providers leverage technology and systems to quickly navigate the initial steps of a patient's treatment journey.

Using Outbound Virtual Engagement Strategies to Break Through Co-Pay Savings Program Plateaus
In this Medical Marketing and Media webcast, Paul Levine, Vice President of Analytics, details how TrialCard’s Virtual Engagement strategies jumpstarted a well-known brand’s stagnant co-pay program, resulting in a $24 million increase in revenue over four months.


Capabilties Brochure Image
Virtual Engagement – A Must-Have Component of any Pharmaceutical Sales Strategy
In this podcast featured by PharmaVOICE, TrialCard's Vice President of Healthcare Professional Engagement, Michael Carlin, talks about how Virtual Engagements are addressing the issue of limited physician access by pharmaceutical reps, including keys to success, measuring results, and the degree of success with these programs.

"I Need to Transition My HUB Program. What Do I Do Next?"
In this podcast, featured by Medical Marketing and Media, TrialCard’s Vice President of Market Access Solutions Scott Dulitz discusses best practices for a successful HUB program transition.

What Does Success Look Like in Patient Affordability?
In this podcast, featured by Medical Marketing and Media, TrialCard’s Vice President of Analytics Paul LeVine explores ways of evaluating patient affordability programs and shares examples of how non-traditional interventions - such as real-world evidence and share-of-voice outreach programs - can amplify their effect.

(Enter your email address below and click submit to download your selected resources)


Please check I'm not a robot for validation.